Publications by authors named "Maria C Pirosa"

Claim this Profile
I
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma.
Maria Cristina Pirosa, Anastasios Stathis, Davide Rossi, Emanuele Zucca

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG).
Annarita Conconi, Andrea Janikova, Barbara Vannata, Ana Florencia Ramírez-Ibarguen, Chiara Lobetti-Bodoni, Maria Cristina Pirosa

Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
Eva Kimby, Sämi Schär, Maria Cristina Pirosa, Anna Vanazzi, Ulrich M Mey

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort.
Luca Ceriani, Lisa Milan, Maria Cristina Pirosa, Maurizio Martelli, Teresa Ruberto

J Nucl Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Maria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35).
Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, Fabiana Esposito, Angela Polino

Hematol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Annarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, Anastasios Stathis, Barbara Botto, Maria Cristina Pirosa

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
Eleonora Calabretta, Martina di Trani, Francesco Corrado, Martina Sollini, Vanessa Cristaldi, Maria Cristina Pirosa

Br J Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival.
Maria Cristina Pirosa, Fabiana Esposito, Giorgio Raia, Vito Chianca, Andrea Cozzi

Radiol Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
Maria Cristina Pirosa, Marianna Sassone, Barbara Kiesewetter, Armando Lopez Guillermo, Liliana Devizzi

Haematologica· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphomas in pregnancy.
Maria Cristina Pirosa, Fedro Alessandro Peccatori

Hematol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Maria Cristina Pirosa

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bacterial infection-driven lymphomagenesis.
Barbara Vannata, Maria Cristina Pirosa, Francesco Bertoni, Davide Rossi, Emanuele Zucca

Curr Opin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma.
Maria Cristina Pirosa, Sven Borchmann, Fabrice Jardin, Gianluca Gaidano, Davide Rossi

Hemasphere· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Maria Cristina Pirosa

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Luca Ceriani, Lisa Milan, Luciano Cascione, Giuseppe Gritti, Federico Dalmasso, Maria Cristina Pirosa

Hematol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.
Sofia Genta, Guido Ghilardi, Luciano Cascione, Darius Juskevicius, Alexandar Tzankov, Maria Cristina Pirosa

Cancers (Basel)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Maria C Pirosa, Lu Zhang, Felicitas Hitz, Urban Novak, Dagmar Hess

Leuk Lymphoma· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, Brendan Hodkinson, Gabriela Forestieri, Maria C Pirosa

Blood Adv· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
Salvatore Leotta, Uros Markovic, Maria Cristina Pirosa, Stefania Stella, Stefania Tringali

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Alden Alberto Moccia, Sämi Schär, Stefanie Hayoz, Maria Cristina Pirosa, Christian Taverna

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, Angela Polino

Blood Adv· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis